ATE434614T1 - 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer - Google Patents

4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer

Info

Publication number
ATE434614T1
ATE434614T1 AT05769611T AT05769611T ATE434614T1 AT E434614 T1 ATE434614 T1 AT E434614T1 AT 05769611 T AT05769611 T AT 05769611T AT 05769611 T AT05769611 T AT 05769611T AT E434614 T1 ATE434614 T1 AT E434614T1
Authority
AT
Austria
Prior art keywords
protein kinase
kinase inhibitors
disubstituted pyrimidines
pyrimidines
disubstituted
Prior art date
Application number
AT05769611T
Other languages
English (en)
Inventor
Josef Stadlwieser
Thomas Baer
Thomas Maier
Thomas Beckers
Thomas Ciossek
Armin Zuelch
Ulrich Graedler
Wolfgang Wirschun
Matthias Herdemann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE434614T1 publication Critical patent/ATE434614T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05769611T 2004-06-28 2005-06-28 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer ATE434614T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103011 2004-06-28
EP05102355 2005-03-23
PCT/EP2005/053019 WO2006000589A1 (de) 2004-06-28 2005-06-28 Novel pyrimidines

Publications (1)

Publication Number Publication Date
ATE434614T1 true ATE434614T1 (de) 2009-07-15

Family

ID=34973043

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05769611T ATE434614T1 (de) 2004-06-28 2005-06-28 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer

Country Status (16)

Country Link
US (1) US7879853B2 (de)
EP (1) EP1763526B1 (de)
JP (1) JP5065017B2 (de)
KR (1) KR20070027723A (de)
CN (1) CN1972934A (de)
AT (1) ATE434614T1 (de)
AU (1) AU2005256659A1 (de)
BR (1) BRPI0512547A (de)
CA (1) CA2570552A1 (de)
DE (1) DE602005015110D1 (de)
ES (1) ES2328601T3 (de)
IL (1) IL179883A0 (de)
MX (1) MXPA06014747A (de)
NO (1) NO20070334L (de)
WO (1) WO2006000589A1 (de)
ZA (1) ZA200609637B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6907921B2 (en) 1998-06-18 2005-06-21 3M Innovative Properties Company Microchanneled active fluid heat exchanger
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE523499T1 (de) 2006-07-06 2011-09-15 Array Biopharma Inc Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
US20090012434A1 (en) * 2007-07-03 2009-01-08 Anderson Robert S Apparatus, method, and system to treat a volume of skin
TWI552752B (zh) * 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
WO2012135781A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
RU2013148817A (ru) 2011-04-01 2015-05-10 Дженентек, Инк. Комбинации соединений-ингибиторов акт и мек и способы их применения
AU2012321091B2 (en) * 2011-10-28 2016-05-12 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US9364476B2 (en) * 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
ME02473B (de) * 2012-04-04 2017-02-20 Amgen Inc Heterocyclische verbindungen und deren verwendungen
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN103483250B (zh) * 2013-10-08 2015-07-22 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN103601675B (zh) * 2013-10-08 2015-10-28 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
EP3179858B1 (de) 2014-08-13 2019-05-15 Celgene Car Llc Formen und zusammensetzungen eines erk-inhibitors
CN113509471B (zh) * 2021-07-19 2023-06-13 中国药科大学 Akt2抑制剂在制备治疗阿霉素引发心肌损伤药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (de) 1994-11-12 1997-12-01 Zeneca Ltd
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
EP1028964A1 (de) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidin- und thienopyridin-derivate als antikrebsmittel
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
EP1246823A1 (de) * 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidin- und triazin kinase-hemmer
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
WO2002012198A2 (en) 2000-08-08 2002-02-14 Ortho-Mcneil Pharmaceutical, Inc. 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
AR035967A1 (es) * 2001-05-18 2004-07-28 Altana Pharma Ag Un compuesto de piridilmetilaminopirimidina, un medicamento que lo comprende y el uso del mismo
HUP0402106A3 (en) 2001-11-01 2009-07-28 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
ES2294190T3 (es) 2001-11-01 2008-04-01 Janssen Pharmaceutica N.V. Derivados de amida como inhibidores de la glucogeno sintasa quinasa 3-beta.
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
EA013811B1 (ru) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2005070900A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
WO2006125616A2 (en) * 2005-05-25 2006-11-30 Ingenium Pharmaceuticals Ag Pyrimidine-based cdk inhibitors for treating pain

Also Published As

Publication number Publication date
WO2006000589A1 (de) 2006-01-05
ZA200609637B (en) 2008-08-27
US20070208034A1 (en) 2007-09-06
CA2570552A1 (en) 2006-01-05
ES2328601T3 (es) 2009-11-16
EP1763526A1 (de) 2007-03-21
EP1763526B1 (de) 2009-06-24
NO20070334L (no) 2007-03-28
KR20070027723A (ko) 2007-03-09
AU2005256659A1 (en) 2006-01-05
DE602005015110D1 (de) 2009-08-06
MXPA06014747A (es) 2007-02-16
JP2008504251A (ja) 2008-02-14
IL179883A0 (en) 2007-05-15
CN1972934A (zh) 2007-05-30
WO2006000589A8 (de) 2006-11-16
US7879853B2 (en) 2011-02-01
BRPI0512547A (pt) 2008-03-25
JP5065017B2 (ja) 2012-10-31

Similar Documents

Publication Publication Date Title
NO20070334L (no) 4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer
DK1567522T3 (da) Pyrimidinforbindelser
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2005116025A3 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
ATE508126T1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
TW200801008A (en) Protein kinase inhibitors
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
HRP20080377A2 (en) ACTIVIN ActRIIa ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
SG154435A1 (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties